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Pegylated interferon-a2b (pIFN-a) is an integral part of the drug regimen currently employed against melanoma. Interferon
regulatory factor-1 (IRF-1) has an important role in the transcriptional regulation of the IFN response, cell cycle and apoptosis.
We have studied pIFN-a-induced responses when combined with the chemotherapy agent, vinblastine (VBL), in tumor and
endothelial cell lines and the connection to IRF-1 signaling. Levels of IRF-1/IRF-2 proteinexpression were found to be decreased
in tumor versus normal tissues. pIFN-a induced IRF-1 signaling in human melanoma (M14) and endothelial (EA.hy926) cells and
enhanced cell death when combined with VBL. Upon combined IFN-a and VBL treatment, p21 expression, poly (ADP-ribose)
polymerasecleavageandactivatedBaklevelswereincreasedinM14cells.Anincreaseinp21andcyclinD1expressionoccurred
in EA.hy926 cells after 6h of treatment with pIFN-a, which dissipated by 24h. This biphasic response, characteristic of cellular
senescence, was more pronounced upon combined treatment. Exposure of the EA.hy926 cells to pIFN-a was associated with an
enlarged, multinucleated, b-galactosidase-positive senescent phenotype. The overall therapeutic mechanism of IFN-a combined
with chemotherapy may be due to both direct tumor cell death via IRF-1 signaling and by premature senescence of endothelial
cells and subsequent effects on angiogenesis in the tumor microenvironment.
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The abysmal median survival for patients with metastatic
melanoma ranges from 6 to 9 months, causing it to be one of
the most aggressive human cancers. The p53 protein acts as
a checkpoint in the cell cycle, either preventing or initiating
programmed cell death. A p53 mutation remains the most
common genetic change identiﬁed in human neoplasia
1
with melanoma exhibiting one of the highest rates of this
oncogenic event.
2
Interferon regulatory factor-1 and -2 (IRF-1 and -2) are two
structurally related members of the IRF family of transcription
factors. Although IRF-1 expression has been associated with
tumorsuppressoractivity,IRF-2expressionhasanoncogenic
effect.
3–5 IRF-1 acts as a tumor suppressor very similar in
function to p53 and regulates the expression of most of the
p53 target genes.
6 It is critical to cell cycle and induction of
apoptosis in response to stress signals.
7,8 The expression of
several genes involved in cell-cycle regulation and apoptosis
such as p21
WAF/cip,
8 p27
Kip1,
9 lysyloxidase,
10 caspase-1,
11
cyclin D1 and CDK4,
12 survivin
13 and Noxa
14 are transcrip-
tionally regulated by IRF-1. By modulating the expression of
VEGF
15 and MMP-9,
16 IRF-1 has also been shown to inhibit
angiogenesis.Thus,the inductionofapoptosisormodiﬁcation
of angiogenic controls by normal IRF-1-driven processes
provide alternative pathways inﬂuential to tumor growth
control. However, similar to mutant p53, this growth control
may be evaded by mutant tumor cells and/or the tumor
microenvironment to allow tumor progression.
The combination of cytotoxic chemotherapy with active
biologicalagentssuchasIL-2andinterferon-a(IFN-a),termed
biochemotherapy, has generated a great deal of interest over
the last several years.
17,18 Adjuvant IFN-a treatment to
prevent the recurrence of melanoma has been encouraging,
yet is likely far from optimized. An additional important
mechanism of the IFN-a-mediated antitumor activity appears
to rely on the interference with tumor-mediated angiogen-
esis.
19,20 There are a number of clinical studies that focus on
the use of IFN-a as an antiangiogenic agent. However, the
true effects of IFN-a in combination with various standard
chemotherapy regimens on the endothelium and/or the
viability of tumor cells are not clearly understood. Interest-
ingly, IFN-a (a standard of care in melanoma) is one of the
agents that induces IRF-1, activating its tumor suppressor
function.
In this study, using human melanoma and endothelial cell
lines, we have observed that treatment with a clinically used
form of pegylated IFN-a treatment in combination with the
chemotherapeutic agent, vinblastine (VBL), induces cell death
via IRF-1-mediated signaling in melanoma cells and concur-
rently induces premature senescence in endothelial cells.
The induction of senescence may be a novel explanation for
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Results
Decrease in the IRF-1/IRF-2 ratio in tumor tissues. The
expression of IRF-1 and -2 can be altered by a host of
factors/agents and thus they may serve as possible targets
for the treatment of cancer. They have been most well
studied in their role as transcription factors active in type I
(IFN-a/b) and type II (IFN-g) signal transduction pathways.
There are several reports indicating that a decrease in the
ratio of IRF-1/IRF-2 expression is prevalent in most tumor
tissue types. In an analysis to study the protein expression
proﬁles of IRF-1 and -2, we were able to show that although
most normal and tumor tissues expressed IRF-1 and -2 the
ratio of IRF-1 to IRF-2 dropped dramatically in the
corresponding tumor tissue samples (Figure 1). This
information builds a case for the relevance of IRF-1 and 2
in cancer biology and treatment.
Enhanced sensitivity of M14 melanoma cells to
combined treatment with IFN-a and VBL. To determine
the cytotoxicity of VBL and pIFN-a, the cells were incubated
with varying concentrations of the drugs at 371C for 72h.
Tetrazolium (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT)) cell proliferation assay was used to
estimate the concentration required to inhibit cell growth by
50% (IC50) for each drug. The IC50 values of VBL and pIFN-a
were approximately 1nM and 0.5mg/ml, respectively, for M14
cells (Figure 2a and b). Cells were treated with constant
concentration of pIFN-a (0.5mg/ml) and the indicated
concentration of VBL (0–10
4pM) for 72h. A greater than
additive cell growth inhibition by MTT assay (70%) was
observed when the cells were treated with a combination of
1nM (10
3pM) VBL and 0.5mg/ml of pegylated IFN-a
(Figure 2c).
The effect of VBL and pegylated IFN-a on cell survival was
also studied by clonogenic assay. Combination of VBL (1nM)
and pIFN-a (0.5mg/ml) was 1.75-fold more toxic to the M14
cells than treatment with VBL (1nM) alone. Treatment with
halftheconcentrationofVBL(0.5nM)andpIFN-a(0.25mg/ml)
was as toxic as treatment with 1nM of VBL alone (Figure 2d).
These studies suggest that combination of pIFN-a and VBL
may enhance the induction of cell death compared with either
treatment alone.
Induction of IRF-1 is speciﬁc to IFN-a exposure and
enhances cell death via IRF-1-mediated signaling in M14
melanoma cells. IRF-1 is a critical transcriptional regulator
in the IFN signaling pathway.
5 Therefore, we investigated the
expression of IRF-1 in response to pIFN-a and VBL in M14
melanoma cells. A dose of 30nM for VBL was selected for
treatment to ensure complete cell death. Cells were treated
at the indicated time points with VBL (30nM) or pIFN-a
(0.5mg/ml) alone and in combination at the same (30nM
VBLþ0.5mg/ml pIFN-a) or at half the concentration of each
agent (15nM VBLþ0.25mg/ml pIFN-a). IRF-1 was induced
by 3–6h and then decreased by 24h in response to pIFN-a
treatment. Interestingly, treatment with 0.25 or 0.5mg/ml
pIFN-a induced the same level of IRF-1. VBL treatment alone
did not cause any noticeable induction of IRF-1. In addition,
IRF-2 did not show any signiﬁcant change in M14 cells after
treatment with either VBL or pIFN-a (Figure 3a).
Subsequently, we looked at the induction of IRF-1 down-
stream targets and cell death in M14 melanoma cells, as
assessed by poly (ADP-ribose) polymerase (PARP) cleavage,
i nr e s p o n s et op I F N - a and VBL individually or combined against
M14 melanoma cells. Transcriptional induction of p21 is
dependent on both p53 and IRF-1.
8M14 cells are p53 defective
and possibly evade cell death by downregulation of p21. We
have observed induction of p21 in M14 melanoma cells by 6h
and subsequent downregulation by 24h in response to pIFN-a
but not VBL (Figure 3b). Except for a delay in the induction of
p21 by 3h, the pattern of p21 protein expression in response to
pIFN-a was similar to the pattern of IRF-1 induction suggestive
of its transcriptional regulation by IRF-1.
Bak is a proapoptotic member of the Bcl-2 family of proteins
and induces cell death by undergoing activation and homo-
oligomerization.
22,23 We observed upregulation of total Bak
in M14 melanoma cells upon treatment with pIFN-a but not
VBL. Further, immunoblotting for PARP revealed that PARP
cleavage, an indicator of cell death, occurs only upon
treatment with VBL. However, combined treatment of VBL
and pIFN-a at half the normal concentration of each agent
(VBL (15nM) and pIFN-a (0.25mg/ml)) caused the same level
of PARP cleavage as treatment with 30nM VBL alone or the
combined treatment (VBL (30nM) and pIFN-a (0.5mg/ml)).
Treatment with pIFN-a alone did not cause PARP cleavage
even by 48h (Figure 3b).
To determine whether combined treatment with pIFN-a and
VBL results in elevated activation of Bak, the conformationally
active form was immunoprecipitated under native conditions
from M14 cells treated for 36h with VBL (30nM) or pIFN-a
(0.5mg/ml) alone and in combination (30nM VBLþ0.5 pIFN-a
mg/ml).Forimmunoprecipitation,weusedrabbitanti-Bak(NT)
antibody (Millipore, Temecula, CA, USA), which recognizes
IRF-1
IRF-2
IRF-1/IRF-2 3.5 2.1 1.9 1.5 1.2 0.4 2.7 1.6 2.0
IRF-1
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Figure 1 Western analysis of IRF-1 and -2 expression in normal human and
tumor tissues. Expression proﬁle of IRF-1 and -2 in normal human tissues (a)o ri n
human tumor samples (b) were analyzed by western immunoblotting (ProSci) and
the IRF-1/IRF-2 ratio was quantiﬁed by densitometry using the Image J software
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Cell Death and Diseasethe conformationally active form of Bak. Cells treated with
pegylated IFN-a had an increased level of inactive Bak
(Supplementary Figure 1). Treatment with VBL caused
inactive Bak to undergo a conformational change and
increased levels of activated protein were detected. Com-
bined treatment with pIFN-a and VBL induced a further
accumulation of active Bak leading to an increase in the total
amount of cell death (Figure 3c).
UsingthetechniqueofBH3proﬁlingdevelopedbyLetaiand
colleagues,
24,25 we observed that a buildup of inactive Bak in
themitochondriaasaconsequenceofpIFN-atreatmentmade
the M14 melanoma cells more sensitive to VBL-induced cell
death (i.e., pIFN-a conditions or primes the cells to death
signaling induced by other agents). The essence of this
technique is to use isolated mitochondria, which contain
inactive Bak, and induce cytochrome c (cyt c) release through
the addition of tBid or Bid (BH3 peptide), which promotes Bak
activation. Mitochondria isolated from M14 melanoma cells
treated with 0.5mg/ml pIFN-a, and subsequently incubated
withanactivator(BH3peptide)ofBak,inducedcytcreleasein
a dose-dependent manner (Figure 3d). In contrast, only low
background levels of cyt c are released from the mitochondria
of untreated cells under similar conditions (Figure 3d).
Evaluation of the response of EA.hy926 endothelial cells
to VBL and/or pIFN-a. Using the MTT assay, EA.hy926
human endothelial cells were found to be relatively more
sensitive to VBL than the M14 melanoma cells with an IC50
between 500pM and 1nM (Figure 4a). The IC50 for pIFN-a in
these cells was B0.5mg/ml (Figure 4b). To test the combined
effect of the drugs, cells were treated with a constant
concentration of pIFN-a (0.5mg/ml) and indicated concen-
tration of VBL (0–500pM) or indicated concentrations of VBL
alone for 72h. Cell growth inhibition measured by MTT assay
was 40% greater with the combined treatment of 500pM VBL
and 0.5mg/ml of pIFN-a in comparison with treatment with
500pM VBL alone (Figure 4c). In subsequent clonogenic
studies, cells were treated with the indicated concentration of
pIFN-a and VBL alone and in combination, and the medium
was replaced with fresh medium without the drugs after 24h.
In contrast to the results from the MTT assay, the
clonogenicity of EA.hy926 cells was found to be markedly
reduced after pIFN-a treatment alone. Combination of VBL
(500pM) and pIFN-a (0.5mg/ml) had a similar effect to that of
pIFN-a alone (Figure 4d).
Induction of IRF-1 in response to pIFN-a and synergistic
response of IRF-1 downstream targets to VBL and
pIFN-a in EA.hy926 endothelial cells. Induction of IRF-1
in EA.hy926 cells that have wild-type p53 was found to occur
by 6h in the presence of pIFN-a but not VBL (Figure 5a, top
panel). Cyclin D1, like p21, is a downstream target of p53
26
and IRF-1.
12 We observed the induction of p21 and cyclin D1
by both VBL and IFN-a. Upregulation of p21 at 6h after
treatment was much greater when EA.hy926 endothelial
cells were treated with VBL and pIFN-a. Half the normal
concentration of the drugs in the combined treatment was
sufﬁcient to cause maximum induction of p21 (Figure 5a,
upper middle panel). Upregulation of cyclin D1 at 6h was
followed by its downregulation by 24h. However, the
Figure 2 Enhancement of M14 cell sensitivity to VBL cytotoxicity by pegylated IFN-a. A total of 3000 cells per well in a 96-well plate were treated with indicated
concentrations of VBL (a) or pegylated IFN-a2b (b) for 72h and subjected to MTT cell viability assay. (c) Cells were treated with the pegylated IFN-a2b (0.5mg/ml) in
combination with the indicated concentrations of VBL (0–10nM) for 72h. Cell proliferation was estimated by MTT assay. (d) Cells (200 cells per well) were treated with the
indicated concentration of drugs for 24h. The cells were rinsed, and fresh medium was added, and after 2 weeks, colonies were stained with crystal violet, counted and the
surviving fraction was calculated. Results in each of the above experiments are the means±S.D. (n¼6). The P-values are shown
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Cell Death and Diseasecombined treatment caused a greater reduction in cyclin D1
at 24h (Figure 5a, lower middle panel). Although the level of
Bak expression tended to vary in the presence of pIFN-a
alone or in combination with VBL, it was completely absent at
48h after treatment with VBL alone (Figure 5b). This
suggests that IFN-a treatment increases and maintains the
level of Bak expression to some extent, a function likely
mediated through IRF-1 activity and also indicated by our
results from western blotting described in Supplementary
Figure 1 and the BH3 proﬁling results shown in Figure 3.
Exposure to IFN-a induces a senescent phenotype in
EA.hy926 endothelial cells. We did not see substantial cell
death even at 1mM IFN-a treatment in the 72h MTT assay
(Figure 4b) but observed a signiﬁcant reduction in cell
survival in the clonogenic studies (Figure 4d). These
perplexing results led us to inspect the doubling time of the
cells after treatment with pIFN-a. Interestingly, although the
control cells doubled in 0.9167 days (about 24h), the pIFN-a-
treated cells failed to increase in total number (Figure 6a).
This loss of the proliferative capacity of EA.hy926 cells was
subsequently observed to be at least partially caused by
pIFN-a-induced senescence. We observed that upon
exposure to pIFN-a, cells became enlarged, ﬂattened,
irregularly shaped and signiﬁcantly more cells expressed
SA b-galþ, suggesting a senescent phenotype (Figure 6b,
middle and lower panel) as compared with untreated cell
cultures (Figure 6b, upper panel).
To observe the effect of pIFN-a on the morphology of
EA.hy926 endothelial cells over time, 1 10
5 cells were
treated for 1, 2 and 6 days with 0.25 and 0.5mg/ml of pIFN-a
and observed at  200 magniﬁcation. Cells treated with IFN-a
for 1 and 2 days were rinsed and grown in fresh medium until
the sixth day. There were signiﬁcantly more cells exhibiting
a senescent phenotype in cultures treated continuously
with 0.5mg/ml of pIFN-a compared with cells treated with
0.25mg/ml of pIFN-a (Supplementary Figure 2a). The cells
were subsequently harvested and replated with fresh medium
into new culture vessels for 2 weeks and again observed by
phase-contrast microscopy. In order to prevent the cells from
being over conﬂuent, only one-ﬁfth of the total cells in the
untreated plate were replated. The senescent phenotype
continued to persist in these freshly plated cells previously
exposed to pIFN-a independent of total length of the initial
exposure to pIFN-a (Supplementary Figure 2b).
Treatment with the microtubule inhibitor, VBL, causes the
cells to arrest at G2/M. Cells tend to get rounded, start ﬂoating
andeventuallyundergocell death.InEA.hy926cells,a similar
Figure 3 Molecular response of M14 melanoma cells to vinblastine (VBL) and IFN-a.( a) IRF-1, and not IRF-2, is induced speciﬁcally in response to pegylated IFN-a in
M14 melanomacells. M14 cells were treated for theindicated timewith either VBL, pegylatedIFN-a2b (pIFN-a), or a combinationof both at the indicatedconcentrations. Cell
extracts (50mg per lane) were immunoblotted for IRF-1 or IRF-2. Immunoblotting for GAPDH served as the loading control. (b) Induction of IRF-1 downstream targets in
response to IFN-a and combined effect of IFN-a and VBL on PARP-induced apoptosis in M14 cells. Cells were treated with the indicated drug concentrations of VBL or
pegylated IFN-a (pIFN-a) and harvested at the given time points. Cell extracts were subjected to immunoblotting for PARP, Bak and p21. Immunoblotting for GAPDH served
astheloadingcontrol.(c)TreatmentofM14cellswithIFN-aandVBLcausesinductionandactivationofBak.M14melanomacellswereuntreatedortreatedwithVBL(30nM)
or pIFN-a (0.5mg/ml) alone or in combination (30nM VBLþ0.5 pIFN-a mg/ml) for 36h. Lysates were immunoprecipitated with anti-Bak-NT antibody for active form of Bak
followed by immunoblotting for Bak. Precipitates prepared in the absence of the antibody ( ) and whole-cell extract (E) were also examined as controls. (d) BH3 peptide-
mediatedcytochromec(cytc)releasefromthemitochondriaofM14melanomacells.Mitochondria(25mgperreaction)isolatedfromM14cellswithoutandaftertreatmentwith
0.5mg/ml IFN-a for 48h were incubated with the indicated concentrations of BH3 peptide for 30min at room temperature. Supernatant was collected and cyt c release was
observed by immunoblotting. DMSO vehicle was 2% ﬁnal in all samples
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Cell Death and Diseasemorphological change was observed by 48h (Supplementary
Figure 3a) upon treatment with 30nM VBL or with a
combination of 15nM VBL and 0.25mg/ml pIFN-a. A quanti-
ﬁcation of adherent versus nonadherent cells after treatment
with pIFN-a and VBL is shown in Supplementary Figure 3b
and represents data from three replicates per condition. As
unsynchronized cells were used for plating, we did observe a
percentage (11%) of nonadherent cells upon IFN-a treatment
as compared with almost 50% of nonadherent cells after VBL
or combined treatment with IFN-a and VBL.
Discussion
The use of pegylated IFN-a2b in monotherapy
27 and in
combination with chemotherapy has been evaluated in
several different types of cancers.
28,29 Pegylated IFN-a2b
with its improved pharmacokinetic proﬁle has been success-
fully introduced into melanoma therapy.
30 However, the most
common adverse effects of neuropsychiatric, hematological
andhepatictoxicityasaconsequenceofIFNtherapyhavenot
been able to be negated and therefore hold the full potential of
this agent in check. Development of optimal protocols for the
use of pegylated IFN-a2b to maximize beneﬁt and minimize
toxicity will allow for wider use with fewer adverse effects.
A detailed understanding of the mechanism of action of IFN-a
alone and in combination with chemotherapy is required to
achieve this goal.
Figure4 SensitivityofEA.hy926endothelialcellstoVBLandpegylatedIFN-a.Atotalof3000cellsperwellina96-wellplateweretreatedwithindicatedconcentrationsof
VBL (a) or pegylated IFN-a2b (b) for 72h and subjected to MTT colorimetric assay. (c) Cells were treated with the pegylated IFN-a2b (0.5mg/ml) in combination with the
indicated concentrations of VBL (0–500pM) for 72h. Cell viability was estimated by MTT assay. The above three ﬁgures were representative of three independent
experiments,theresultsofeacharethemeans±S.D.(n¼6).(d)Atotalof2000cellsperwellinasix-wellplateweretreatedwiththeindicatedconcentrationofdrugsfor24h.
The cells were rinsed, fresh medium was added, and after 2 weeks, colonies were stained with crystal violet, counted and the surviving fraction was calculated
Figure 5 Induction of IRF-1 and its downstream targets in response to pIFN-a
and VBL in EA.hy926 endothelial cells. Cells were treated with the indicated
concentrations of VBL or pegylated IFN-a (pIFN-a) and harvested at the given time
points. Cell extracts were subjected to immunoblotting for (a) IRF-1, p21 and cyclin
D1, and (b) Bak. Immunoblotting for GAPDH served as the loading control
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Cell Death and DiseaseOwing to the ability of IFNs to enhance immunogenicity,
IFN signaling and IFN therapy have been extensively studied
with regard to levels of tumor immunity attained. Other non-
immune-based molecular mechanisms have been studied at
the cellular level in response to IFNs, but have not readily
beenconnectedwithtumor/tumormicroenvironmentresponse.
Recent evidence has broadened the scope of IRF-1 tumor
suppressor functions in a variety of cancers, including ovarian
cancer,
31 melanoma,
4 breast cancer
32 and cervical cancer.
33
Here, we have shown that there is a substantial fall in the
IRF-1/IRF-2 ratio in tissues from nine different types of human
tumors when compared with the corresponding normal tissue
(Figure 1). This may not just serve as a useful indicator for
diagnosis and prognosis of most tumors (Figure 1) but
enables their use as possible targets in cancer treatment.
A series of viability and survival studies indicated that pIFN-
a enhances the sensitivity of the M14 melanoma cells to cell
death by the cytotoxic agent, VBL (Figure 2). At the molecular
level, although IRF-1 gets speciﬁcally induced in response to
pIFN-a, the level of IRF-2 remains more or less constant
(Figure 3a) and it is known that IRF-1 is involved in cell-cycle
regulation and induction of apoptosis. For instance, transcrip-
tional induction of p21 by g-irradiation was dependent on both
IRF-1andp53.
8p21isacyclin-dependentkinaseinhibitorand
regulates cell-cycle progression at S phase.
34 The M14
melanoma cell line is p53 defective and thus one possible
alternate route to induction of p21 is through upregulation of
IRF-1 (Figure 3b).
We also observed distinct PARP cleavage, suggestive of cell
death induction, upon VBL treatment after 24h. pIFN-a treatment
alonedidnotcauseanyPARPcleavageevenby48h(Figure3b).
We investigated the possible role of Bak induction and activation
in the greater than additive cell death caused by VBL combined
with pIFN-a. Bak, a distal mediator of apoptosis, undergoes
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Figure 6 Induction of senescence-like growth arrest in EA.hy926 endothelial cells in response to pIFN-a.( a) In all, 5 10
4 EA.hy926 cells were plated onto 60mm Petri
plates and on the next day treated with 0.25 or 0.5mg/ml of IFN-a and counted on the sixth day after treatment. (b) The cells treated in the same manner were stained for
senescence-associated b-galactosidase at 48h after treatment and phase-contrast images of cells were taken at  200 magniﬁcation. Scale bar¼100mm
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Cell Death and Diseaseconformational changesandhomo-oligomerizationinresponseto
diverse apoptotic signals, leading to pore formation in the
mitochondria and release of apoptosis-promoting factors.
22,23
TheexpressionofBakhasbeenshown to be upregulated byIRF-
1
35(Figure3b).ActivationofBakisacriticalsteptowardapoptosis
involving the exposure of its N-terminal epitope. Previously, we
showed that VBL induces activation of Bak in KB-3 cells.
23
Importantly, although there is a signiﬁcant increase in Bak
expression in response to pIFN-a (Figure 5b), we show in the
present report, using a conformationally dependent Bak antibody,
that only VBL induces Bak activation in M14 melanoma cells
(Figure 3c). It appears that the combined treatment of pIFN-aand
VBL allows for an accumulation of total Bak and a subsequent
increaseinoverallactivationofBakinM14melanomacells,which
leads to enhanced cell death by the combined treatment.
Using an alternate strategy, we have also demonstrated
that the buildup of inactive Bak in response to pIFN-a
treatment sensitizes the M14 melanoma cell mitochondria
to BH3 peptide-mediated cyt c release (Figure 3d). This
relationship thus suggests that the pIFN-a treatment primes
M14 melanoma cells to more rapidly respond to cell death
stimuli such as that exerted by VBL and possibly other
chemotherapeutics.Inductionofp21andBakviaupregulation
of IRF-1 in response to pIFN-a might partially explain how the
IFN signaling pathway crosstalks with the other apoptotic and
cell-cycle pathways to enhance cell death in M14 melanoma
cells and may have implications for other tumor cell types.
The progressive growth and metastasis of most tumors are
angiogenesis dependent and therefore controlled by not only
tumor cell proliferation but also proliferation and activity of
cells that form the microvasculature.
19,20 We selected the
humanEA.hy.926endothelialcelllinetobetterunderstandthe
possible effects of pIFN-a exposure on tumor microvascu-
lature mediated by endothelial cell responses (Figure 4).
EA.hy926 is an immortalized endothelial cell line harboring
wild-type p53. It has been shown that the transcriptional
induction of the p21 gene is dependent on both p53 and
IRF-1.
8 Cyclin D1, which works in concert with p21 to promote
progression through G1,
36 has also been shown to be
transcriptionally regulated by p53
26 and IRF-1.
12 These two
tumor suppressor transcription factors therefore converge
functionally to regulate cell cycle and possibly senescence
throughtheactivationofcommontargetgenes.Itappearsthat
sensitivity to cell death is enhanced in cells in which both p53
and IRF-1-mediated pathways can be activated such as in
normal cells of the stromal compartment that supports the
tumor microenvironment (Figure 5).
Our initial results from the treatment of EA.hy926 cells with
pIFN-a were perplexing. While on one hand MTT cell viability
assay did not show complete or substantial cell death even at
1mM IFN-a treatment (Figure 4b), long-term survival studies
showed a signiﬁcant reduction in number of colonies when
treated with 0.5mg/ml IFN-a (Figure 4d). This increase in
sensitivity to IFN-a was not due to the extent of apoptotic
cell death (data not shown) but rather associated with
enlarged,multinucleated, b-galactosidase-positive senescent
EA.hy926 endothelial cells (Figure 6a). Although the normal
cells doubled in less than 1 day, the number of cells in tissue
culture plates after 5 days of IFN-a treatment remained
constant. This suggested an alternate mechanism to apoptotic
or clonogenic cell death may be at play. Indeed, we observed
a premature senescence phenotype induced in IFN-a-treated
cellsthatpersistedforlongtermoversubsequentpassagesof
the cells. Induction of a senescent phenotype has previously
been observed after treatment with several DNA-binding
drugs.
37 The EA.hy926 endothelial cells studied here
exhibited a similar phenotype and an induction followed
by a subsequent decrease in the levels of p21
and cyclin D1 upon treatment with pIFN-a and VBL (Figure 5).
This biphasic response of p21 and cyclin D1 is a further
characteristic of cellular senescence.
38,39 Therefore, our
results suggest that the normally proliferative tumor endo-
thelium in a growing malignant tissue environment may be
sensitive to pIFN-a-induced senescence, which would be
expected to modify the angiogenic activity in the tumor. We
have also demonstrated (Supplementary Figure 3) that VBL
treatment, which causes G2/M arrest, followed by apoptosis
results in nonadherent cells that do not undergo senescence.
In summary, our results suggest that the overall therapeutic
mechanism of IFN-a combined with chemotherapeutic agents
may be due to direct tumor cell death via IRF-1-based signaling
and by inducing premature senescence in endothelial cells,
which could reduce the angiogenic activity in the tumor. These
results further uncover alternate mechanisms by which IFN-a
functions in cancer therapy. An increased understanding of how
the IFN-a pathway crosstalks with other pathways via IRF-1-
based signaling to control apoptosis in the tumor microenviron-
ment appears to be a valid approach to better identify drug
regimens suited to block angiogenesis and cell proliferation in
melanoma and other solid tumors. Efforts are underway to study
these interconnections in cocultures and in in vitro angiogenic
coculture constructs of tumor and endothelial cells.
Materials and Methods
Cell lines and culture. M14 is a human malignant melanoma cell strain,
originally denoted as UCLA-SO-M14, later called M14, which expresses most
melanoma-associated markers.
40,41 EA.hy926 is an immortalized human endothelial-
like cell line derived from the fusion of primary human endothelial vein endothelial cells
with the lung carcinoma cell line A549.
42 The cell lines were maintained in monolayer
culture at 371C and 5% CO2. The M14 human melanoma cell line was maintained in
RPMI (Cellgro, Manassas, VA, USA), supplemented with 10% fetal bovine serum
(Atlas, Fort Collins, CO, USA), 50units/ml penicillin and 50mg/ml streptomycin
(Hyclone, Logan, UT, USA). The EA.hy926endothelial cell line was cultured in DMEM/
F-12 (Cellgro) with 10% bovine calf serum (Hyclone), 2mM L-glutamine, 100 units/ml
penicillin, 100mg/ml streptomycin and 1:50 HAT (Cellgro).
Chemicals and reagents. Pegylated IFN-a2b (PEGINTRON) referred as
pIFN-a was purchased from Schering-Plough (Kenilworth, NJ, USA). VBL and
thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich
(St Louis, MO, USA). IRF-1, IRF-2 and cyclin D1 (DCS-6) antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Bak (NT) antibody for
immunoprecipitation was from Millipore and Bak (Ab-1) antibody for immunoblotting
was from Oncogene (Boston, MA, USA). Glyceraldehyde-3-phosphate
dehydrogenase antibody was from Cell Signaling Technology (Danvers, MA,
USA). Cytochrome c and p21antibodies werefrom BD Pharmingen(San Jose,CA,
USA). Crystal violet (Fisher Scientiﬁc, Fairlawn, NJ, USA) and protein A/G PLUS-
agarose beads were from Santa Cruz Biotechnology.
MTT cell viability assay. Cells (2000 per well) were seeded in 96-well plates
andon thefollowingday VBLand/or pIFN-a wasadded.After72h, MTT(50mgper
well) was added for 4h followed by dimethylsulfoxide solubilization of the cells, and
an absorbance reading was done at 540nm.
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culture plates and on the next day treated with the indicated concentration of drugs for
24h,and then colony formation was assessed. Cells wereallowed togrowfor 2weeks
after rinsing and replenishing the wells with fresh media without the drugs at 24h.
Colonies werestained withcrystal violet and countedto calculatethesurvivingfraction.
Expression of IRF-1 and -2 in normal human and tumor
tissues. Customized western blots (ProSci Inc., Poway, CA, USA) of 15
normal human and tumor tissues each were probed for IRF-1 (1:1000). The blots
were stripped and reprobed for IRF-2 (1:1000). The level of IRF-1 and -2 protein
expressionwasestimatedbyanalyzingtherelativebandintensitiesusingtheImage
J software (NIH, Bethesda, MD, USA).
Preparation of cell extracts and immunoblotting. Whole-cell extracts
were prepared by suspending cells in 0.25ml of lysis buffer (25mM HEPES, pH 7.5,
0.5% sodium deoxycholate, 5mM EDTA, 5mM dithiothreitol, 20mM glycerophosphate,
1mMNa 3VO4,5 0m MN a F ,1 %T r i t o nX - 1 0 0 ,2 0mg/ml aprotinin, 50mg/ml leupeptin,
10mMp e p s t a t i n ,1 mM okadaic acid and 1mM phenylmethylsulfonyl ﬂuoride). Cells
were incubated at 41C on a nutator for 1h, insoluble material was removed by
centrifugation (15min at 12000 g) and protein concentration was determined using
the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA).
BH3 peptide-mediated mitochondrial cyt c release. Mitochondria
(25mg per reaction) isolated from M14 cells without and after treatment with
0.5mg/ml pIFN-a for 48h were incubated with the indicated concentrations of
BH3 peptide for 30min at room temperature. Supernatant was collected and cyt c
release was observed by immunoblotting. DMSO was used as the vehicle (2% ﬁnal
concentration in all samples).
24
Immunoprecipitation. ToevaluateBakactivationstatus,thecellswerelysed
in0.5mlof10mMHEPES(pH7.4),150mMNaCl,1%CHAPS,plusproteaseinhibitors
(as above) and incubated at 41C for 45min on nutator. The cell extract was centrifuged
at 12000 g for 15min, and 500mg of cell lysate was precleared using protein A/G-
PLUS agarose beads for 30min followed by incubation with 4mg of Bak(NT) polyclonal
antibody (Millipore) in a total of 500ml of lysis buffer for 1h. The lysates were then
incubated with 25ml of protein A/G-agarose beads (Santa Cruz Biotechnology)
overnight at 41C. The beads were pelleted by centrifugation and washed three times
with 0.2ml of lysis buffer. The beads were resuspended in 50mlo f2  SDS loading
buffer and electrophoresed on 12.5% SDS-PAGE precast acrylamide gels (Bio-rad).
Following electrophoresis, immunoblotting was performed using mouse anti-Bak (Ab-1)
monoclonal antibody (Oncogene) at 1:1000 dilution.
23
Senescence associated-b-Gal assay. The SA-b-Gal assay was
performed as previously described in the manufacturer’s instructions
(Senescence b-galactosidase staining kit, Cell Signaling Technology). Brieﬂy,
cells were washed in phosphate-buffered saline and ﬁxed in 2% formaldehyde–
0.2% glutaraldehyde. Then the cells were washed and incubated at 371C overnight
withfreshsenescence-associatedb-Galstainsolution(1mgof5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside (X-Gal per ml), 40mM citric acid–sodium phosphate
(pH 6.0), 150mM NaCl, 2mM MgCl2, 5mM potassium ferrocyanide, 5mM
potassium ferricyanide). For all visualization and photography, a Nikon Eclipse
Te2000-U microscope (Kanagawa, Japan) was used.
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